Интерстициальное поражение легких при системной склеродермии
Диссертация
Практическая значимость. Предложен алгоритм инструментального обследования больных ССД для выявления поражения легких и оценки легочной функции, который может служить основой для диагностики и мониторирования ИПЛ, а также выбора терапии. Алгоритм включает проведение спирометрии и определение ДСЛ на первом этапе обследования, а при выявлении нарушений — проведение КТВР в качестве второй ступени… Читать ещё >
Список литературы
- Георгиади С.Г., Котляров П. М. Компьютерно томографические признаки диффузных заболеваний легких // Вестник, РНЦРР МЗ РФ. — 2004.- № 4. — С. 20−25.
- Патофизиология легких // Гриппи М. А. М., Бином.- 2005. — 130−141 с.
- Системная склеродермия и псевдосклеродермические синдромы // Гусева Н. Г. М., Медицина. — 1993. — 75−82 с.
- Гусева Н.Г. Проблемы диагностики и лечения системной склеродермии // Рус. мед. журн.- 1998.- № 8(68). С. 482−486.
- Гусева Н.Г. Системная склеродермия: клиника, диагностика, лечение // Российский журнал кожных и венерических болезней. 2002.- 4. — С.5−15.
- Интерстициальные заболевания легких // Илькович М. М., Кокосов А. Н. -СПб: Нордмедиздат. 2005. — 231−242 с.
- Интерстициальные болезни легких // Коган Е. А., Коренев Б. М., Попова Е. Н. и др. М., Литера. — 2007. — 186−191 с.
- Мониторинг состояния здоровья населения Российской Федерации. Российский мониторинг экономического положения и здоровья населения 1992−2001 гг. Университет Северной Каролины в Чэпел Хилле и Институт социологии РАН. 2002.
- Клиническая ревматология // Насонова В. А., Астапенко М. Г. М., Медицина. — 1989. — 175−193 с.
- Компьютерная томография органов грудной полости // Тюрин И. Е. -ЭЛБИ-СПб. 2003. — 324−330 с.
- Рентгеновская компьютерная томография в диагностике заболеваний легких и средостения // Харченко В. П., Глаголев Н. А. М. — Медика. — 2005. 74−75 с.
- Клинические рекомендации. Пульмонология / Чучалин А. Г. М., ГЭОТАР-Медиа. — 2007. — 1−37 с.
- Afeltra A., Zennaro D., Garzia P. et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography // Scand. J. Rheumatol. 2006. — 35(5). — P. 388−394.
- Akesson A., Scheja A., Lundin A. et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide // Arthritis Rheum. -1994.-37(5).-P. 729−735.
- Altman R.D., Medsger T.A. Jr, Bloch D.A. et al. Predictors of survival in systemic sclerosis (scleroderma)// Arthr. Rheum. 1991. — 34(4). — P. 403−413.
- Andonopoulos A.P., Yarmenitis S., Georgiou P. et al. Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography // Clin. Exp. Rheumatol. 2001. — 19(2). — P. 187−190.
- Bag L.R., Hughes D.T. Serial pulmonary function tests in progressive systemic sclerosis // Thorax. 1979. — 34. — P. 224−228.21 .Basu D., Reveille J.D. Anti-scl-70. // Autoimmunity. 2005. — 38(1). — P. 65−72.
- Battle R.W., Davitt M.A., Cooper S.M. et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma // Chest. 1996. — 110(6). — P. 1515−1519.
- Berman J.S. Lymphocytes in the lung: should we continue to exalt only BALT? //Am. J. Respir. Cell Mol. Biol. 1990. — 3(2). — P. 101−102.
- Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome // Am. J. Respir. Crit. Care Med. 2002. — 165(12). — P. 1581−1586.
- Briggs D.C., Vaughan R.W., Welsh K.I. et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis // Lancet. 1991. — 338(8768). — P. 661−662.
- Bryan C., Knight C., Black C.M. et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit // Arthr. Rheum. 1999. — 42(12).- P. 26 602 665.
- Bulpitt K.J., Clements P.J., Lachenbruch P.A. et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis) // Ann. Intern. Med. 1993. — 118(8). — P. 602 609.
- Caccavo D., Afeltra A., Rigon A. at al. Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement // Int. J. Immunopathol. Pharmacol. 2008. — 21(3). — P. 659−667.
- Catoggio L.J., Bernstein R.M., Black C.M. et al. Serological markers in progressive systemic sclerosis: clinical correlations // Ann. Rheum. Dis. 1983. — 42(1). — P. 23−27.
- Catterall M., Rowell N.R. Respiratory function in progressive systemic sclerosis // Thorax. 1963. — 18. — P. 10−15.
- Chwiesko S., Kowal-Bielecka O., Sierakowski S. Cyclophosphamide treatment in patients with systemic sclerosis // Postepy. Hig. Med. Dosw. 2006. — 60. — P. 300−306.
- Clements P., Goldin J., Kleerup E. et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspno patients with systemic sclerosis // Arthr. Rheum. 2004. — 50. -P. 1909−1917.
- Clements P.J., Roth M.D., Elashoff R. at al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis // Ann. Rheum. Dis. 2007. — 66(12). — P. 1641−1647.
- Colaci M., Sebastiani M., Giuggioli D. et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis // Scand. J. Rheumatol. 2010.-39(2).-P. 155−159.
- Colp C.R., Riker J., Williams M.H. Jr. Serial changes in scleroderma and idiopathic interstitial lung disease // Arch. Intern. Med. 1973. — 132(4). — P. 506−515.
- D’Angelo W.A., Fries J.F., Masi A.T. et al. Pathologic observations in systemic sclerosis (scleroderma):a study of fifty-eight autopsy cases and fifty-eight matched controls // Am. J. Med. 1969. — 46. — P. 428−440.
- Davas E.M., Peppas C., Maragou M. et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma // Clin. Rheumatol. 1999. — 18(6). — P. 455−61.
- Denton C.P., Cailes J.B., Phillips G.D. et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis // Br. J. Rheumatol. 1997. — 36(2). — P. 239 243.
- Desai S.R., Veeraraghavan S., Hansell D.M. et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia // Radiology. 2004. — 232(2). -P. 560−567.
- De Santis M., Bosello S., La Torre G. et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis //Respir. Res. 2005. — 17. — P. 96.
- Dev6nyi K., Czirjak L. High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma // Clin. Rheumatol. 1995. — 14(6). — P. 633−640.
- Diot E., Giraudeau В., Diot P. et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? // Chest. 1999. — 116(3). — P. 715−720.
- Du Clos T.W. C-reactive protein as a regulator of autoimmunity and inflammation // Arthritis Rheum. 2003. — 48(6). — P. 1475−1477.
- Fenlon H.M., Doran M., Sant S.M. et al. High-resolution chest CT in systemic lupus erythematosus // AJR Am. J. Roentgenol.- 1996. 166(2). — P. 301−307.
- Flaherty K.R., Mumford J.A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia // Am. J. Respir. Crit. Care Med. 2003 Sep l-168(5):543−8. Epub 2003 May 28.
- Flaherty K.R., Towes G.B., Travis W.D. et al. Clinical significance of histologic classification of idiopathic interstizial pneumonia // Eur. Respir. J., -2002.- 19.-P. 275−283.
- Gabbay E., Tarala R., Will R. et al. Interstitial lung disease in recent onset rheumatoid arthritis // Am. J. Respir. Crit. Care Med. 1997. — 156(2 Pt 1). — P. 528−535.
- Garber S.J., Wells A.U., duBois R.M. et al. Enlarged mediastinal lymph nodes in the fibrosing alveolitis of systemic sclerosis // Br. J. Radiol. 1992. -65(779). — P. 983−986.
- Geirsson A.J., Wollheim F.A., Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale // Ann. Rheum. Dis. 2001. — 60(12). — P. 1117−1122.
- Giacomelli R., Valentini G., Salsano F. et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis // J. Rheumatol. 2002. -29(4). P. 731−436.
- Godfey S., Bluestone R., Higgs B.E. Lung function and the response to exercise in systemic sclerosis // Thorax. 1969. — 24. — P. 427−434.
- Goh N.S., Desai S.R., Veeraraghavan S. at al. Interstitial lung disease in systemic sclerosis: a simple staging system // Am. J. Respir. Crit. Care Med. -2008.- 177(11).-P. 1248−1254.
- Goldin J.G., Lynch D.A., Strollo D.C. et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease // Chest. 2008. — 134(2). — P. 358−367.
- Greenwald G.I., Tashkin D.P., Gong H. et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study //Am. J. Med. 1987. — 83(1). — P. 83−92.
- Greidinger E.L., Flaherty K.T., White B. et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease // Chest. 1998. — 114(3). — P. 801−807.
- Guttadauria M., Ellman H., Emmanuel G. et al. Pulmonary fimction in scleroderma//Arthritis Rheum. 1977. — 20. — P. 1071−1079.
- Guttadauria M, Sarojo D, Gopintham P et al. Small airway disease in scleroderma//Arthritis Rheum. 1975. — 18. — P. 283−284.
- Harrison N.K., Glanville A.R., Strickland B. et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance // Respir. Med. 1989. -83(5). P. 403−414.
- Harrison N.K., Myers A.R., Corrin B. et al. Structural features of interstitial lung disease in systemic sclerosis // Am. Rev. Respir. Dis. 1991. — 144(3 Pt 1). -P. 706−713.
- Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients // Ann. Rheum. Dis. 1998. — 57. -P. 682−686.
- Highland K.B., Silver R.M. Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study // Curr. Rheumatol. 2005. — 7(2).-P. 135−141.
- Ikezoe J., Johkoh Т., Kohno N. et al. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis // J. Thorac Imaging. 1996.- 11(4).-P. 250−259.i
- Jacobsen S., Halberg P., Ullman S. et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis // Clin. Rheumatol. 1997. -16(4).-P. 384−390.
- Jacobsen S., Ullman S., Shen G.Q. et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis // J. Rheumatol. 2001. — 28(11). — P. 2454−2459.
- Kahaleh M.B., Sultany G.L., Smith E.A. et al. A modified scleroderma skin scoring method.//Clin. Exp. Rheumatol. 1986. — 4(4). — P. 367−369.
- Kallenberg C.G.M., Jansen H.M., Elema J.D. et al. Steroidresponsive interstitial pulmonary disease in systemic sclerosis: monitoring by bronchoalveolar lavage // Chest.- 1984. 86. — P. 489−492.
- Kaloudi О., Miniati I., Alari S. Interstitial lung disease in systemic sclerosis. // Intern. Emerg. Med. 2007. — 2(4). — P. 250−255.
- Kampolis C., Plastiras S., Vlachoyiannopoulos P. et al. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis // Scand. J. Rheumatol. 2008. — 37(4). -P. 278−283.
- Kanoh S., Kobayashi H., Motoyoshi K. et al. Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases // Chest. 2005. -128(4). — P. 2387−2392.
- Kim E.A., Johkoh Т., Lee K.S. et al. Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation // J. Comput. Assist. Tomogr. 2001. — 25(5). — P. 757−763.
- Kim D.S., Yoo В., Lee J.S. et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia // Sarcoidosis Vase. Diffuse Lung Dis. 2002. — 19(2). — P. 121−127.
- Koh E.T., Lee P., Gladman D.D. et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients // Br. J. Rheumatol. 1996. — 35(10). — P. 989−993.
- Kusume K. Lung injury in idiopathic pulmonary fibrosis and measurement of immunoreactive neutrophil elastase and alpha 1-protease inhibitor in blood // Nihon Kyobu Shikkan Gakkai Zasshi. 1991. — 29(10). — P. 1254−1260.
- Lally E.V., Jimenez S.A., Kaplan S.R. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients // Semin. Arthritis Rheum. 1988. — 18(1). — P. 1−13.
- Latsi P.I., Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma // Curr. Opin. Rheumatol. 2003. — 15(6). — P. 748 755.
- Lee P., Langevitz P., Alderdice C.A. et al. Mortality in systemic sclerosis (scleroderma)// Q. J. Med. 1992. — 82(298). — P. 139−148.
- Lei Y.X., Zhang X., Cui Y. et al. Clinical analysis of 79 pulmonary arterial hypertension cases from 1892 connective tissue disease patients // Zhonghua Yi Xue Za Zhi. 2009. — 89(41). — P. 2934−2937.
- LeRoy E.C., Black C., Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis // J. Rheumatol. 1988. — 15(2). — P. 202−205.
- Linenthal H., Talkov R. Pulmonary fibrosis in Raynaud’s disease // N. Engl. J. Med.- 194.-P. 682−684.
- Manoussakis M.N., Constantopoulos S.H., Gharavi A.E. et al. Pulmonary involvement in systemic sclerosis. Association with anti-Scl 70 antibody and digital pitting // Chest. 1987. — 92(3). — P. 509−513.
- Marcisz C., Kucharz E.J., Brzezinska-Wcislo L. et al. Pulmonary functional abnormalities in asymptomatic patients with systemic sclerosis // Eur. J. Intern. Med. 2003. — 14(3). — P. 162−165.
- Maricq H.R., Weinrich M.C., Keil J.E. et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina // Arthr. Rheum. 1989.-32(8).-P. 998−1006.
- McNearney T.A., Reveille J.D., Fischbach M. et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors // Arthr. Rheum. 2007. — 57(2). — P. 318−326.
- Medsger T.A. Classification of Systemic sclerosis //In Systemic sclerosis: Scleroderma edited by M.I.V Jayson and C.M. Black. 1988.
- Medsger T.A., Jr, Silman A.J., Steen V.D. at al. A disease severity scale for systemic sclerosis: development and testing // J. Rheumatol. 1999. — 26(10). -P. 2159−2167.
- Morgan С., Knight С., Lunt M et al. Predictors of end stage lung disease in a cohort of patients with scleroderma // Ann. Rheum. Dis. 2003. — 62(2). — P. 146−150.
- Mukerjee D., St George D., Knight C. et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis // Rheumatology (Oxford). 2004. — 43(4). — P. 461−466.
- Nagai S., Kitaichi M., Itoh H. et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP //Eur. Respir. J. 1999. — 13(3). — P. 711.
- Nagy Z., Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis // Clin. Exp. Rheumatol. 2005 — 23(2). — P. 165−172.
- Nicholson A.G., Wells A.U. Nonspecific interstitial pneumonia: nobody said it’s perfect // Am. J. Respir. Crit. Care Med. 2001. — 164(9). — P. 1553−1554.
- Owens G.R., Fino G.J., Herbert D.L. et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma // Chest. 1983. — 84(5). — P. 546−50.
- Pakas I., Ioannidis J.P., Malagari K. et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease // J. Rheumatol. -2002. 29(2). — P. 298−304.
- Parra E.R., Otani L.H., de Carvalho E.F. et al. Systemic sclerosis and idiopathic interstitial pneumonia: histomorphometric differences in lung biopsies // J. Bras. Pneumol. 2009. — 35(6). — P. 529−540.
- Peters-Golden M., Wise R.A., Schneider P. et al. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis // Medicine
- Baltimore). 1984. — 63(4). — P. 221−231.
- Quadrelli S.A., Molinari L., Ciallella L.M. et al. Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemicsclerosis // Rheumatol. Int.- 2009. 29(9). — P. 995−999.
- Remy-Jardin M., Remy J., Wallaert B. Pulmonary involvement in progressive systemic sclerosis sequential evaluation with CT, pulmonary tests and broncho-alveolar lavage // Radiology. 1993. — 188. — P. 499−506.
- Renzoni E., Rottoli P., Coviello G. et al. Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease // Clin. Rheumatol. 1997. — 16(6). — P. 570−577.
- Rizou C., Ioannidis J.P., Panou-Pomonis E. et al. B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis // Am. J. Respir. Cell. Mol. Biol. 2000. — 22(3). -p. 344−351.
- Rossi G.A., Bitterman P.B., Rennard S.I. et al. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis // Am. Rev. Respir. Dis. 1985. — 131(4). — P. 612−617.
- Ruangjutipopan S., Kasitanon N., Louthrenoo W. et al. Causes of death and poor survival prognostic factors in thai patients with systemic sclerosis // J.
- Med. Assoc. Thai. 2002. — 85(11). — P. 1204−1209.
- Sahhar J., Littlejohn G., Conron M. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment // Intern. Med. J. 2004. -34(11). — P. 626−638.
- Schneider P.D., Wise R.A., Hochberg M.C. et al. Serial pulmonary function in systemic sclerosis // Am. J. Med. 1982. — 73(3). — P. 385−394.
- Schurawitzki H., Stiglbauer R., Graninger W. et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography // Radiology. 1990. — 176(3). — P. 755−759.
- Sergiacomi G., De Nardo D., Capria A. et al. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis // In Vivo. 2004. — 18(2). — P. 229−235.
- Silman A.J. Epidemiology of scleroderma// Curr. Opin. Rheumatol. 1991. — 3(6). — P. 967−972.
- Silva C.I.S., Muller N.L., Hansell D.M. et al. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time // Radiology. 2008. — 247 (1). — P. 251−259.
- Silver R.M., Miller K.S. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage // Am. J. Med. 1990. — 88. — P. 470−476.
- Silver R.M., Warrick J.H., Kinsella M.B. et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease // J. Rheumatol. 1993. — 20(5). — P. 838−844.
- Song E., Ouyang N., Horbelt M. et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts // Cell. Immunol. 2000. — 204(1). — P. 19−28.
- Spagnolatti L., Zoia M.C., Volpini E. et al. Pulmonary function in patients with systemic sclerosis // Monaldi. Arch. Chest. Dis.- 1997. 52(1). — P. 4−8.
- Standardization of Spirometry, 1994 Update. American Thoracic Society // Am. J. Respir. Crit. Care Med. 1995. — 152(3). — P. 1107−1136.
- Steen V. Predictors of end stage lung disease in systemic sclerosis // Ann Rheum. Dis. 2003. — 62(2). — P. 97−99.
- Steen V.D. The lung in systemic sclerosisM/V J. Clin. Rheumatol. 2005. -11(1).-P. 40−46.
- Steen V., Chou M., Shanmugam V. et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis // Chest. 2008. -134(1).-P. 146−151.
- Steen V.D., Conte C., Owens G.R. Severe restrictive lung disease in systemic sclerosis // Arthr. Rheum. 1994. — 37(9). — P. 1283−1289.
- Steen V.D., Graham G., Conte C. et al. Isolated diffusing capacity reduction in systemic sclerosis // Arthritis Rheum. 1992. — 35(7). — P. 765−770.
- Steen V.D., Lanz J.K. Jr., Conte C. et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study // Arthritis Rheum. 1994 -37(9).-P. 1290−1296.
- Steen V.D., Medsger T.A. Jr. Long-term outcomes of scleroderma renal crisis // Ann. Intern. Med. 2000. — 17. — P. 600−603.
- Steen V.D., Medsger T.A., Severe organ involvement in systemic sclerosis with diffuse scleroderma // Arthr. Rheum. 2000. — 43. — P. 2437−2444.
- Steen V.D., Medsger T.A.Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneus involvement // Arthtr. Rheum. 2003. — 48. P. 516−522.
- Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972−2002 // Ann. Rheum. Dis. 2007. — 66(7). — P. 940−944.
- Steen V.D., Owens G.R., Fino G.J. et al. Pulmonary involvement in systemic sclerosis (scleroderma) // Arthritis Rheum. 1985. — 28(7). — P. 759 767.
- Steen V.D., Owens G.R., Redmond C. et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis // Arthritis Rheum. 1985. — 28(8). -P. 882−888.
- Steen V.D., Ziegler G.L., Rodnan G.P. et al. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis // Arthritis Rheum. 1984. — 27. — P. 125−131.
- Strange C., Bolster M.B., Roth M.D. et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease // Am. J. Respir. Crit. Care Med. 2008. — 177(1). — P. 91−98.
- Stratton R.J., Coghlan J.G., Pearson J.D. et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma // QJM. 1998. — 91(8). — P. 561−566.
- Stratton R.J., Pompon L., Coghlan J.G. et al. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension // Ann. Rheum. Dis. 2000. — 59(2). — P. 132−134.
- Stuart R.A., Littlewood A.J., Maddison P.J. at al. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders // Clin. Exp. Rheumatol. 1995. — 13(1). — P. 17−22.
- Stupi A.M., Steen V.D., Owens G.R. et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis // Arthritis Rheum. 1986. -29(4). P. 515−524.
- Tager R.E., Tikly M. Clinical and laboratory manifestations of systemic sclerosis in black South Africans // Rheumatology (Oxford). 1999. — 38. — P. 397−400.
- Tajima S., Oshikawa K., Tominaga S., et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis // Chest. -2003. 124(4). — P. 1206−1261.
- Tashkin D.P., Clements P.J., Wright R.S. et al. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis // Chest. 1994. — 105(2). — P. 489−495.
- Tashkin D.P., Elashoff R., Clements P.J. et al. Cyclophosphamide versus placebo in scleroderma lung disease // N. Engl. J. Med. 2006. — 354(25). — P. 2655−2666.
- Tazelaar H.D., Viggiano R.W., Pickersgill J. et al. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings // Am. Rev. Respir. Dis. 1990. — 141(3). — P. 727−733.
- Varai G., Earle L., Jimenez S.A. et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease // J. Rheumatol. 1998.- 25(7). — P. 1325−1329.
- Vlachoyiannopoulos P.G., Dafni U.G., Pakas I et al. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1 * 1104 allele // Ann. Rheum. Dis. 2000. — 59(5). — P. 359−367.
- Volpinari S., La Corte R., Bighi S. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters // Rheumatol. Int. 2010. — 32. — P. 45 -46
- Wanchu A., Suryanaryana B.S., Sharma S. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study // Int. J. Rheum. Dis. 2009. — 12(3). — P. 239−242.
- Warrick J.H., Bhalla M., Schabel S.I. High resolution computed tomography in early scleroderma lung disease // J. Rheumatol. 1991. 18(10). — P. 15 201 528.
- Weaver A.L., Divertie M.B., Titus J.L. Pulmonary scleroderma // Dis. Chest. 1968.- 54(6).-P. 490−498.
- Wechsler R.J., Steiner R.M., Spirn P.W. et al. The relationship of thoracic lymphadenopathy to pulmonary interstitial disease in diffuse and limited systemic sclerosis: CT findings // AJR Am. J. Roentgenol. 1996. — 167(1). — P. 101−104.
- Weiner E.S., Earnshaw W.C., Senecal J.L. et al. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients // Arthritis Rheum. 1988. — 31(3). — P. 378−385.
- Wells AU, Cullinan P, Hansell DM et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis // Am J Respir Crit Care Med. 1994. — 149(6). — P. 1583−1590.
- Wells A.U., Hansell D.M., Corrin B. et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis // Thorax. -1992.-47(9).-P. 738−742.
- Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance // Am. J. Respir. Crit. Care Med. 1994. — 150(2). — P. 462−468.
- Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography // Arthr. Rheum. 1997. — 40(7). — P. 1229−1236.
- Wells A.U., Hansell D.M., Haslam P.L. et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis // Am. J. Respir. Crit. Care Med. 1998. — 157(5 Pt 1).-P. 1474−1482.
- White В., Moore W.C., Wigley F.M. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis // Ann. Intern. Med. 2000. — 132. — P. 947−954.
- Witt C., Borgess A.C., John M. et al. Pulmonary involvement in difuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis //Ann. Rheum. Dis. 1999. 98. — P. 635−640.к
- Yamane К., Ihn Н., Asano Y., Yazawa N. et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension // Rheumatology (Oxford). 2000. — 39(11). — P. 1269−1271.